Regencell Bioscience Holdings Limited (RGC) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Causeway Bay, Hong Kong. The current CEO is Yat-Gai Au.
RGC has IPO date of 2021-07-16, 12 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $14.89B.
Regencell Bioscience Holdings Limited is a Traditional Chinese medicine bioscience company incorporated in 2014 and headquartered in Causeway Bay, Hong Kong. The company specializes in the research, development, and commercialization of TCM-based treatments for neurocognitive disorders and degeneration, with a primary focus on attention deficit hyperactivity disorder and autism spectrum disorder. Through its integrated approach to traditional medicine and modern science, Regencell aims to address significant unmet medical needs in neurological health.
